Cargando…

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Detalles Bibliográficos
Autores principales:	Schimmer, Roman R., Kovtonyuk, Larisa V., Klemm, Nancy, Fullin, Jonas, Stolz, Sebastian M., Mueller, Jan, Caiado, Francisco, Kurppa, Kari J., Ebert, Benjamin L., Manz, Markus G., Boettcher, Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198927/ https://www.ncbi.nlm.nih.gov/pubmed/35026842 http://dx.doi.org/10.1182/bloodadvances.2021005859

Ejemplares similares

Aging drives Tet2(+/−) clonal hematopoiesis via IL-1 signaling
por: Caiado, Francisco, et al.
Publicado: (2023)

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
por: Sperling, Adam S., et al.
Publicado: (2022)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Assessment of TP53 Mutations in Benign and Malignant Salivary Gland Neoplasms
por: Gomes, Carolina Cavaliéri, et al.
Publicado: (2012)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

CXCL12-abundant reticular cells are the major source of IL-6 upon LPS stimulation and thereby regulate hematopoiesis
por: Gerosa, Rahel C., et al.
Publicado: (2021)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
por: Li, Junjie, et al.
Publicado: (2021)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment
por: Yoshida, Reiko, et al.
Publicado: (2022)

Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels
por: Wilk, C. Matthias, et al.
Publicado: (2022)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Expression of TP53, BCL-2, and VEGFA Genes in Esophagus Carcinoma and its Biological Significance
por: Wei, Wei, et al.
Publicado: (2015)

Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection
por: Caiado, Francisco, et al.
Publicado: (2019)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

Epstein-Barr virus infection mediated TP53 and Bcl-2 expression in nasopharyngeal carcinoma pathogenesis
por: Vatte, Chittibabu, et al.
Publicado: (2021)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Author Correction: Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection
por: Caiado, Francisco, et al.
Publicado: (2019)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment
por: Kovtonyuk, Larisa V., et al.
Publicado: (2016)

Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2016)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Cell proliferation, cell loss and expression of bcl-2 and p53 in human pulmonary neoplasms.
por: Kennedy, M. M., et al.
Publicado: (1997)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
por: Chernak, Brian J., et al.
Publicado: (2020)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0uja201tjmhhd52t08agvpacvf